Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.45 |
| ▸ | VNN1 | O95497 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6989302 | 0.87 | CNR1 (0.58) | CNR1TRPV1LTA4HEPHX2PPARG | |
| SCHEMBL6476422 | 0.85 | MTNR1A (0.63) | CNR1MTNR1AMTNR1BCHRM2CHRM1 | |
| SCHEMBL3939774 | 0.83 | PPARA (0.51) | CNR1PPARGPPARACHRM2CHRM1 | |
| SCHEMBL15818398 | 0.81 | PPARA (0.55) | CNR1PPARGPPARACHRM2CHRM1 | |
| SCHEMBL1869446 | 0.80 | POLB (0.50) | CNR1PPARGPPARACHRM2CHRM1 | |
| SCHEMBL27422506 | 0.79 | CNR1 (0.67) | CNR1TRPV1LTA4HEPHX2CHRM2 | |
| SCHEMBL7643257 | 0.79 | CNR1 (0.63) | CNR1TRPV1LTA4HEPHX2MTNR1A | |
| SCHEMBL3255177 | 0.79 | PPARA (0.52) | CNR1PPARGPPARACHRM2CHRM1 | |
| SCHEMBL6482686 | 0.78 | HDAC3 (0.64) | MTNR1AMTNR1BPOLB | |
| SCHEMBL16839828 | 0.78 | CETP (0.51) | CNR1LTA4HCHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6930114-B2 | Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-08-16 | — | — | US | disclosed |
| US-20040138249-A1 | Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors | BAYER PHARMACEUTICALS CORPORATION | 2004-07-15 | — | — | US | disclosed |
| US-20030236276-A1 | Pyrrolo[2.1-a]isoquinoline derivatives | NIEWOHNER ULRICH (DE) | 2003-12-25 | — | — | US | disclosed |
| EP-1347973-A1 | PYRROLO (2.1-A) DIHYDROISOQUINOLINES AND THEIR USE AS PHOSPHODIESTERASE 10A INHIBITORS | Bayer Aktiengesellschaft (DE) | 2003-10-01 | — | — | EP | disclosed |
| WO-2003014116-A1 | PYRROLO[2.1-A]ISOQUINOLINE DERIVATIVES | BAYER CORPORATION (US) | 2003-02-20 | — | — | WO | disclosed |
| WO-2002048144-A1 | PYRROLO (2.1-A) DIHYDROISOQUINOLINES AND THEIR USE AS PHOSPHODIESTERASE 10A INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236276-A1 | Pyrrolo[2.1-a]isoquinoline derivatives | PDE5A, PDE2A, PDE3A | CNR1 3202/4885TRPV1 2579/4885LTA4H 1925/4885 |
| US-20040138249-A1 | Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors | PDE7B, PDE2A, PDE5A | CNR1 3290/4885TRPV1 3490/4885LTA4H 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.